Final Program

WEDNESDAY • MAY 18 383
P966
P967
P968
P969
P970
P971
P972
P973
Facilitator:
P974
P975
P976
P977
Diagnostic Accuracy and Concordance of Different Criteria for
Exercise Pulmonary Hypertension/L. Godinas, E. Lau, D.
Chemla, F. Lador, L. Savale, D. Montani, O. Sitbon, G. Simonneau,
M.J.C. Humbert, P. Herve, Le Kremlin Bicetre, France, p.A7333
Time-Constant of the Pulmonary Arterial Windkessel in
Precapillary Pulmonary Hypertension: A Reappraisal/E. Lau, D.
Chemla, K. Zhu, V. Castelain, P. Attal, M. Humbert, P. Herve,
Sydney, Australia, p.A7334
Comparison of Different Types of Pulmonary Hypertension in
Patients with Connective Tissue Disease/G. Mazzanti, M. Palazzini,
A. Manes, C. Bachetti, E. Gotti, F. Dardi, A. Rinaldi, A. Albini, E. Monti,
S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A7335
End Tidal CO2 as a Predictor of Outcomes in Patients with
Pulmonary Arterial Hypertension/C.E. Welch, I.M. Robbins, E.L.
Brittain, J.H. Newman, A.R. Hemnes, Nashville, TN, p.A7336
Mechanisms of Gas Exchange Impairment in Chronic
Obstructive Pulmonary Disease (COPD) with Severe
Pulmonary Hypertension/L. Piccari, I. Blanco, Y. Torralba, F.
Burgos, C. Gistau, J. Roca, R. Rodriguez-Roisin, J.A. Barbera,
Barcelona, Spain, p.A7337
The Ratio of Pulmonary Artery Over Wedge Nitrite Predicts the
Pulmonary Vascular Response to Inhaled Nitric Oxide in
Idiopathic Pulmonary Arterial Hypertension/A.R. Tonelli, M.K.
Ahmed, W. Dakkak, K. Aulak, R. Dweik, Cleveland, OH, p.A7338
The Prevalence of Pulmonary Hypertension in Patients with
Multiple Myeloma/U. Krishnan, T.M. Mark, R. Niesvizky, M. Karas,
I. Sobol, New York, NY, p.A7339
Patient Characteristic Cluster Analysis Predicts Response to
Therapy to Oral Treprostinil in Pulmonary Arterial
Hypertension/K.S. Parikh, Y. Rao, K. Shen, S. Rajagopal,
Durham, NC, p.A7340
M.G. Risbano, MD, MA, Pittsburgh, PA
Bisoprolol in Idiopathic Pulmonary Arterial Hypertension: A
Sub-Group Analysis in Patients with Low Versus High Right
Ventricular Ejection Fraction/J.S. Van Campen, K.D. Boer, M.C.
Van De Veerdonk, C.E. Van Der Bruggen, C.P. Allaart, M.W.
Heymans, J.T. Marcus, F.S. De Man, A. Vonk Noordegraaf, H.J.
Bogaard, Den Haag, Netherlands, p.A7341
The Geometry of the Right Ventricle from CT Scans as a
Predictor of Pulmonary Vascular Disease in Smokers in the
COPDGene Study/J.K. Minhas, F.N. Rahaghi, G.
Vegas-Sanchez-Ferrero, R.P. Bowler, J.M. Wells, C.E. Come, I. De
La Bruere, B. Fenster, G. Gonzalez, A.A. Diaz, P. Kohli, S.P. Bhatt,
D.A. Lynch, M.T. Dransfield, R. San Jose Estepar, G. Washko,
Boston, MA, p.A7342
Long Term Health Outcomes of Individuals with High Altitude
Pulmonary Hypertension: A 55 Year Follow Up Study/
J.C. Robinson, C. Abbott, R.C. Roach, B. Honigman, T.M. Bull,
Aurora, CO, p.A7343
Galectin-3 and Aldosterone as Potential Tandem Biomarkers in
Pulmonary Arterial Hypertension/G. Hansmann, L. Calvier, E.
Legchenko, L. Grimm, H. Sallmon, A. Hatch, B.D. Plouffe, C.
Schroeder, J. Bauersachs, S.K. Murhy, Hannover, Germany,
p.A7344
P978
P979
P980
P981
P982
P983
P984
P985
Facilitator:
P986
P987
P988
P989
P990
Fick Principle Determinants of the 6-Minute Walk Test (6-MWT)
Distance/R. Badr Eslam, R.K. Oliveira, J.A. Tracy, A.L. Karin, M.
Agarwal, A. Waxman, D. Systrom, Vienna, Austria, p.A7345
Impact of Intrathoracic Pressure in the Assessment of
Pulmonary Vascular Pressure/A. Jawad, A.R. Tonelli, R.L.
Chatburn, U. Hatipoglu, Cleveland, OH, p.A7346
Pulmonary Venous Hypertension in Patients with Systemic
Sclerosis: Baseline Characteristics and Survival/K. Bourji, R.L.
Damico, B. Kelemen, S.C. Mathai, T. Kolb, R. Tedford, P.M.
Hassoun, Baltimore, MD, p.A7347
Pulmonary Arterial Hypertension (PAH) Specific Therapy
Induce Changes in L-Arginine and Methylarginines Compared
to Baseline Values in Healthy Subjects and Patients with Heart
Failure/A.M. Sandqvist, D. Henrohn, D. Kylhammar, J. Lundgren,
J. Schneede, G. Radegran, G. Wikstrom, Umea, Sweden, p.A7348
The Potential Use of Left Atrial to Right Atrial Size Ratio in
Discriminating Idiopathic Pulmonary Arterial Hypertension
from Pulmonary Hypertension Due to Heart Failure with
Preserved Ejection Fraction/A. Huis In ‘t Veld, L. Handoko, O.A.
Spruijt, H.J. Bogaard, A. Vonk Noordegraaf, Amsterdam,
Netherlands, p.A7349
Impact of Pulmonary Arterial Hypertension on Dynamic
Cerebral Autoregulation/S. Malenfant, P. Brassard, M. Paquette,
O. Le Blanc, A. Chouinard, S. Bonnet, S. Provencher, Quebec City,
Canada, p.A7350
Role of Cardiac Magnetic Resonance in Stratifying the
Prognosis of Patients with Pulmonary Arterial Hypertension/F.
Dardi, C. Bachetti, M. Palazzini, G. Mazzanti, E. Gotti, A. Rinaldi, A.
Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna,
Italy, p.A7351
Defining The Role of Balloon Pulmonary Angioplasty (BPA):
U.S. High-Volume Pulmonary Thromboendarterectomy (PTE)
Single-Center Experience/D.S. Poch, E. Mahmud, M. Patel, M.M.
Madani, N.H. Kim, La Jolla, CA, p.A7352
N.S. Hill, MD, Boston, MA
Pulmonary Arterial Capacitance as an Indicator of Response to
Therapy in Pulmonary Arterial Hypertension/S. Medrek, C.A.
Kloefkorn, Z. Safdar, Houston, TX, p.A7353
Breath Volatolome for the Detection of Pulmonary Arterial
Hypertension/M. Nakhleh, M. Humbert, E. Fadel, H. Haick, S.
Cohen-Kaminsky, Le plessis Robinson, France, p.A7354
Elevated Bilirubin Levels Are Associated with Intrapulmonary
Vascular Dilation in Patients wtih Cirrhosis/S. Chuzi, L.B.
VanWagner, R. Kalhan, M. Cuttica, Chicago, IL, p.A7355
Toward Theranostic Biomarkers in Pulmonary Hypertension/
A.C. Swaminathan, A. Poms, K. Kennedy, H. Zhu, E. Gaspard, T.A.
Fortin, J. Senick, K. Parikh, Z.T. Kelleher, B. Fee, S. Rajagopal, K.
Murray, V. Tapson, T.J. McMahon, Durham, NC, p.A7356
Riociguat Treatment for Porto-Pulmonary Hypertension: A
Subgroup Analysis from the PATENT-1 Study/R. Cartin-Ceba,
M. Halank, H.-A. Ghofrani, M. Humbert, J. Mattson, A. Fritsch, M.J.
Krowka, Scottsdale, AZ, p.A7357
WEDNESDAY MORNING
ATS 2016 • San Francisco